Takeda Pharmaceutical Company L (TAK) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $16.71, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3); Thin upside margin: 3.3%.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived... Read more
Sell if holding. At $16.71, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3); Thin upside margin: 3.3%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $16.71, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3); Thin upside margin: 3.3%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $16.14. Score 4.9/10, moderate confidence.
Take-profit target: $17.24 (+3.2% upside). Prior stop was $16.14. Stop-loss: $16.14.
Thin upside margin: 3.3%; Consecutive earnings misses (3); Weak overall score: 4.9/10.
Takeda Pharmaceutical Company L trades at a P/E of 74.1 (forward 30.8). TrendMatrix value score: 6.5/10. Verdict: Sell.
19 analysts cover TAK with a consensus score of 3.7/5. Average price target: $20.
What does Takeda Pharmaceutical Company L do?Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing...
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.